Who is Octapharma?
Octapharma is a privately owned company that specialises in the development, manufacture and sale of high-quality human proteins derived from human plasma for use as pharmaceuticals and medical treatments. Headquartered in Lachen, Switzerland, Octapharma’s mission is "for the safe and optimal use of human proteins". Since its foundation in 1983, Octapharma has become one of the key manufacturers in the global plasma industry. The organisation was founded on the principal of enhancing the lives of patients across the world. Click here for more.
How is Octapharma different from other plasma companies?
Octapharma is an independent private company with a high degree of flexibility and specialisation. Focusing exclusively on human protein products, we have achieved a number of innovations over 30 years: the first company to apply the solvent detergent (SD) virus inactivation method to routine production; the first company to launch high-purity, virus inactivated Factor VIII and Factor IX concentrates; the first company to launch a liquid immunoglobulin preparation; the first company to launch virus-inactivated plasma for transfusion.
In which countries are Octapharma's products available?
Octapharma has trade partners throughout the world. Active in over 100 countries globally, Octapharma continues to expand into new territories and increase its global footprint. Click here to view the world map for contact details of our global locations.
Where does Octapharma source its plasma?
Octapharma obtains plasma as raw material for its products exclusively from carefully selected and approved plasma donation centres and owns and operates centres in the United States and Germany. Click to view the plasma centre world map
Where does Octapharma produce its products?
Octapharma owns production plants in Vienna, Austria; Lingolsheim, France; Springe, Germany; Stockholm, Sweden; and Mexico City, Mexico. A sixth plant in Dessau, Germany for packaging. Click here to find out more about Octapharma’s Production Plants.
Where are the research centres of Octapharma located?
Octapharma’s research centres are located in Europe. The R&D Plasma Group consists of R&D Plasma in Vienna, Austria; Virus & Prion Validation in Frankfurt, Germany; and Molecular Biochemistry in Berlin, Germany. The R&D Recombinant Group is located in Heidelberg, Germany. Octapharma’s Clinical R&D Haematology is located in Lachen, Switzerland. Clinical R&D Immunology and Intensive Care & Emergency Medicine is located in Vienna, Austria.
What is the focus of Octapharma´s R&D?
Since its establishment, Octapharma has continuously developed ever-more sophisticated technologies in order to provide effective biopharmaceuticals to satisfy unmet patient needs. The underlying principle for Octapharma’s R&D is the development of therapies to treat diseases within our three therapeutic areas. These therapies will be based on human proteins, either purified from human plasma or produced by recombinant technologies applied to human cell lines.
Does Octapharma support education programmes?
Octapharma, in collaboration with healthcare professionals, organise and run national and international programmes to support disease diagnosis and treatment pathways. To find out about future events, please contact your local regional office. Click here to access our locations map
Is Octapharma involved in scientific congresses?
Octapharma support global and regional scientific congresses across the three therapeutic areas. During these meetings Octapharma organise educational and scientific symposia with the healthcare community. Examples of the these global meetings include, the World Federation of Haemophilia, European Association of Haemophilia Disorders, International and Patient Organisation of Primary Immunodeficiency.
For more questions, please contact us.